Impact of IL-6 receptor inhibition on human memory B cells in vivo: Impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells

Annals of the Rheumatic Diseases

Volumn 70, Issue 8, 2011, Pages 1507-1510

  Muhammad, Khalid ^a   Roll, Petra ^a   Seibold, Thomas ^a   Kleinert, Stefan ^a   Einsele, Hermann ^a   Dörner, Thomas ^b,c   Tony, Hans Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; ETANERCEPT; IMMUNOGLOBULIN RECEPTOR; TOCILIZUMAB;

ARTICLE; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE REARRANGEMENT; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; MEMORY CELL; MOLECULAR INTERACTION; MUTATION RATE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN MOTIF; RHEUMATOID ARTHRITIS; SOMATIC HYPERMUTATION; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTE SUBSETS; FEMALE; GENE REARRANGEMENT, B-LYMPHOCYTE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959807954     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.141325     Document Type: Article

References (20)

1. Lipsky PE. Interleukin-6 and rheumatic diseases. Arthritis Res Ther 2006;8(Suppl 2):S4.
2. Dienz O, Eaton SM, Bond JP, et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med 2009;206:69-78.
3. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988;167:332-44. (Pubitemid 18073639)
4. Nishimoto N. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol 2005;28:221-30.
5. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
6. Garnero P, Thompson E, Woodworth T, et al. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010;62:33-43.
7. Roll P, Muhammad K, Schumann M, et al. In vivo effect of the anti interleukin-6 receptor inhibitor tocilizumab on the B-cell compartment. Arthritis Rheum. Published Online First: January 18 2011. doi:10.1002/art.30242. .
8. Dörner T, Foster SJ, Brezinschek HP, et al. Analysis of the targeting of the hypermutational machinery and the impact of subsequent selection on the distribution of nucleotide changes in human VHDJH rearrangements. Immunol Rev 1998;162:161-71. (Pubitemid 28182133)
9. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004;13:339-43. (Pubitemid 38788493)
10. Weller S, Braun MC, Tan BK, et al. Human blood IgM 'memory' B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 2004;104:3647-54.
11. Liang B, Gardner DB, Griswold DE, et al. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006;119:296-305. (Pubitemid 44571047)
12. Martinez-Gamboa L, Mei H, Loddenkemper C, et al. Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. Clin Immunol 2009;130:199-212.
13. Wu Y, Sukumar S, El Shikh ME, et al. Immune complex-bearing follicular dendritic cells deliver a late antigenic signal that promotes somatic hypermutation. J Immunol 2008;180:281-90.
14. Wu Y, El Shikh ME, El Sayed RM, et al. IL-6 produced by immune complex-activated follicular dendritic cells promotes germinal center reactions, IgG responses and somatic hypermutation. Int Immunol 2009;21:745-56.
15. Dörner T, Foster SJ, Farner NL, et al. Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. Eur J Immunol 1998;28:3384-96. (Pubitemid 28470285)
16. Petersen-Mahrt SK, Harris RS, Neuberger MS. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 2002;418:99-103. (Pubitemid 34742579)
17. Monson NL, Foster SJ, Brezinschek HP, et al. The role of CD40-CD40 ligand (CD154) interactions in immunoglobulin light chain repertoire generation and somatic mutation. Clin Immunol 2001;100:71-81.
18. Yoshida H, Hashizume M, Suzuki M, et al. Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells. Eur J Pharmacol 2010;634:178-83.
19. Vital EM, Dass S, Rawstron AC, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010;62:1273-9.
20. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010;62:542-52.